Compare Fubotv Inc (FUBO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Fubotv Inc trades at $8.84 (market cap $1.02B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 9.9× Fubotv Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FUBO | XBI | |
|---|---|---|
Market Cap | $1.02B | $10.11B |
Volume | 978,631 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $48.96 | $169.55 |
52-Week Low | $8.09 | $104.99 |
Typical Hold Time | 35 Days | 38 Days |
Enterprise Value | $1.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.35, up 1.08% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported revenue of $1.62 billion in 2024, with a net loss of $172.25 million, though the net income margin improved to -10.62%. Recent news highlights strategic partnerships with the NHL and The Athletic to expand sports content offerings. Analyst consensus is a Buy with a $63.38 price target, but cash flow remains negative, and the stock is heavily shorted.
The outlook for FUBO hinges on its ability to achieve profitability through subscriber growth and cost management. Opportunities include leveraging Disney's operational expertise and new sports distribution deals. Key risks are persistent cash burn, high debt levels, and intense competition in the streaming sector. The stock presents a speculative opportunity with significant upside if turnaround efforts succeed, but investors should be cautious of execution risks and market volatility.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
